MSFP
ARTV

Mark Sheptoff Financial Planning’s Artiva Biotherapeutics ARTV Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.88K Hold
400
– – ﹤0.01% 467
2026
Q1 		$4.24K Hold
400
– – ﹤0.01% 450
2025
Q4 		$1.72K Hold
400
– – ﹤0.01% 480
2025
Q3 		$1.15K Hold
400
– – ﹤0.01% 459
2025
Q2 		$604 Hold
400
– – ﹤0.01% 493
2025
Q1 		$1.2K Sell
400
-500
-56% -$2.7K ﹤0.01% 417
2024
Q4 		$9.07K Sell
900
-400
-31% -$4.8K ﹤0.01% 325
2024
Q3 		$20.1K Buy
+1,300
New +$15.1K 0.01% 246

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Mark Sheptoff Financial Planning's ARTV Position: Q2 2026 in Review

Mark Sheptoff Financial Planning held its Artiva Biotherapeutics (ARTV) position steady in Q2 2026 at 400 shares worth $3.88K. The position accounts for ﹤0.01% of the portfolio, ranked #467.

Mark Sheptoff Financial Planning first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $20.1K in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Mark Sheptoff Financial Planning held 400 shares of Artiva Biotherapeutics worth $3.88K as of Q2 2026.
  • Mark Sheptoff Financial Planning left its Artiva Biotherapeutics share count unchanged in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Mark Sheptoff Financial Planning's portfolio in Q2 2026, its #467 holding.
  • Mark Sheptoff Financial Planning first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Mark Sheptoff Financial Planning's Artiva Biotherapeutics position peaked at $20.1K in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q2 2026, filed 13 Aug 2026.